The Human Tissue (Quality and Safety for Human Application) Regulations 2007

PART 1 U.K. CITATION, COMMENCEMENT, EXTENT AND INTERPRETATION

Citation and commencement U.K.

1.—(1) These Regulations may be cited as the Human Tissue (Quality and Safety for Human Application) Regulations 2007.

(2) Except as provided by paragraph (3), these Regulations shall come into force on 5 July 2007.

(3) These Regulations shall come into force on the day after the day on which they are made so far as necessary to enable anything (including the fixing of fees) to be done for the purposes of granting, varying, suspending or revoking licences in respect of activities required by virtue of these Regulations to be authorised by a licence on the commencement date.

Extent and application U.K.

2.—(1) These Regulations extend to England and Wales and Northern Ireland.

(2) Parts 1 to 5 and 7 of, and the Schedules to, these Regulations also extend to Scotland.

(3) These Regulations shall not apply in relation to the processing, preservation, storage, distribution, import and export of tissue or cells for use in manufactured products, including medical devices, to the extent that such activities are regulated by—

(a) the Medicines (Homeopathic Medicinal Products for Human Use) Regulations 1994 M1 ,

(b) the Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994 M2 ,

(c) the Medical Devices Regulations 2002 M3 , or

(d) the Medicines for Human Use (Clinical Trials) Regulations 2004 M4 .

(4) Paragraph (3) does not limit the application of the amendments made by Part 6 of these Regulations.

Marginal Citations

M1 SI 1994/105, as amended by SI 1994/899, SI 1995/541, SI 1996/482, SI 1998/574, SI 1999/566, SI 2001/795, SI 2002/236 and 542, SI 2003/623 and 2321, SI 2004/666 and SI 2005/2753.

M2 SI 1994/3144, as amended by SI 1998/3105, SI 2000/292, SI 2001/795, SI 2002/236, SI 2003/2321, SI 2004/3224, SI 2005/50, 768 and 2759 and SI 2006/1952.

M3 SI 2002/618, as amended by SI 2003/1697, SI 2005/2759 and 2909.

M4 SI 2004/1031, as amended by 2005/2754 and 2759 and SI 2006/1928 and 2984.

Designation of the competent authority U.K.

3.  The Human Tissue Authority (in these Regulations referred to as “ the Authority”) is designated the competent authority for the purposes of the first, second and third Directives so far as they relate to tissue and cells.

References to Directives U.K.

4.  In these Regulations—

“the first Directive” means Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells M5 ,

“the second Directive” means Commission Directive 2006/17/EC implementing Directive 2004/23/EC of the European Parliament and of the Council of 8 February 2006 as regards certain technical requirements for the donation, procurement and testing of human tissues and cells M6 , and

“the third Directive” means Commission Directive 2006/86/EC implementing Directive 2004/23/EC of the European Parliament and of the Council of 24 October 2006 as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells M7 .

Marginal Citations

M5 OJ L102, 7.4.2004, p.48.

M6 OJ L38, 9.2.2006, p.40.

M7 OJ L294, 25.10.2006, p.32.

Interpretation of other terms U.K.

5.—(1) In these Regulations—

“the 2004 Act” means the Human Tissue Act 2004 M8 ;

“autologous graft” means tissue or cells removed from and applied in the same person within the same surgical procedure;

“blood” means whole human blood collected from a donor and processed either for transfusion or for further manufacturing;

“blood component” means a therapeutic constituent of human blood (red cells, white cells, platelets and plasma) that can be prepared by various methods, but does not include lymphocytes intended for use for the purpose of haematopoietic stem cell transplantation;

“the commencement date” means 5 July 2007;

“cells” means individual human cells or a collection of human cells when not bound by any form of connective tissue, including cell lines grown outside the human body but not including—

(a)

gametes,

(b)

embryos outside the human body, or

(c)

blood and blood components;

“designated individual”, in relation to a licence under Schedule 1, means the individual designated in the licence as the person under whose supervision the licensed activity is authorised to be carried on;

“export” means export from the United Kingdom to a place outside the United Kingdom;

“human application”, in relation to tissue or cells, means use on or in a human recipient, including use in extracorporeal applications but not including use for autologous graft;

“import” means import into the United Kingdom from a place outside the United Kingdom;

“licence holder” means a person who holds a licence under Schedule 1;

“licensed activity”, in relation to a licence, means an activity which the licence authorises under Schedule 1;

“relevant third party premises” has the meaning given by regulation 6(2);

“serious adverse event” means any untoward occurrence which may be associated with the procurement, testing, processing, storage or distribution of tissue or cells intended for human application and which, in relation to a donor of tissue or cells intended for human application or a recipient of tissue or cells—

(a)

might lead to the transmission of a communicable disease, to death, or life-threatening, disabling or incapacitating conditions, or

(b)

might result in, or prolong, hospitalisation or morbidity;

“serious adverse reaction” means an unintended response, including a communicable disease, in a donor of tissue or cells intended for human application or a recipient of tissue or cells, which may be associated with the procurement or human application of tissue or cells and which is fatal, life-threatening, disabling, incapacitating or which results in, or prolongs, hospitalisation or morbidity;

“storage” means maintaining tissue or cells, whether by preservation or in any other way, for more than 48 hours, and “store” is to be interpreted accordingly;

“tissue” means all constituent parts of the human body formed by cells, but does not include—

(a)

gametes,

(b)

embryos outside the human body, or

(c)

organs or parts of organs if it is their function to be used for the same purpose as the entire organ in the human body;

“third party” has the meaning given by regulation 6(2); and

“third party agreement” has the meaning given by regulation 6(1).

(2) Subject to paragraph (1) and except as otherwise provided in these Regulations, words and expressions used in these Regulations have the same meaning as in Article 3 of the first Directive, Article 1 of the second Directive and Article 2 of the third Directive (definitions).

(3) Subject to paragraphs (1) and (2) and except as otherwise provided in these Regulations, words and expressions used in these Regulations have the same meaning as in the 2004 Act as amended by these Regulations.

(4) For the purposes of these Regulations—

(a) a person who, from any premises, controls the provision of services for transporting tissue or cells is to be taken to distribute tissue or cells on those premises; and

(b) any reference to a requirement of any provision of the first, second or third Directive is a reference to a requirement which the provision requires be imposed in relation to the procurement, testing, processing, storage, distribution, import or export of tissue or cells intended for human application.

Marginal Citations

M8 2004 c.30.

References to third party agreements etc U.K.

6.—(1) For the purposes of these Regulations a third party agreement is an agreement in writing between a licence holder (or the designated individual on behalf of the licence holder) and another person, which is made in accordance with any directions given by the Authority under section 23(1) of the 2004 Act for the purpose of securing compliance with the requirements of Article 24 of the first Directive (relations between tissue establishments and third parties), and under which the other person—

(a) carries on a licensed activity (other than storage), on behalf of the licence holder, or

(b) supplies to the licence holder any goods or services which may affect the quality or safety of tissue or cells.

(2) In these Regulations—

“relevant third party premises”, in relation to a licence under Schedule 1, means any premises (other than premises to which the licence relates)—

(a)

on which a third party procures, tests, processes or distributes, or to which a third party imports or from which a third party exports, tissue or cells on behalf of any person authorised by a licence to carry on that activity, or

(b)

from which a third party provides any goods or services which may affect the quality or safety of tissue or cells to any person in connection with licensed activities carried on by that person; and

“third party” means a person with whom a licence holder has a third party agreement.